Gregory Riely: Updated NCCN guidelines for treatment of patients with thymoma and thymic carcinoma
Gregory Riely, Medical oncologist at Memorial Sloan Kettering Cancer Center, shared on X:
“Updated NCCN guidelines for treatment of patients with thymoma and thymic carcinoma were released.
For thymic carcinoma, there are some new additions for treatment options in both first line and second line.
For first line treatment of thymic carcinoma, the regimen of carboplatin, paclitaxel, and ramucirumab was added, based on RELEVENT trial with response rate of 58% and median PFS was 18.1 months.
Authors: C Proto, M Ganzinelli, S Manglaviti, M Imbimbo, G Galli, M Marabese, F Zollo, M F Alvisi, M Perrino, N Cordua, F Borea, F de Vincenzo, A Chella, S Cappelli, E Pardini, Z Ballatore, A Lucarelli, E Ambrosini, M Giuliano, E Pietroluongo, C Mulargiu, A Fabbri, A Prelaj, M Occhipinti, M Brambilla, L Mazzeo, T Beninato, R Vigorito, M Ruggirello, F G Greco, G Calareso, D Miliziano, E Rulli, I De Simone, V Torri, F G M de Braud, G Pasello, P De Placido, R Berardi, I Petrini, P Zucali, M C Garassino, G Lo Russo
In subsequent therapy for thymic carcinoma, regimen of avelumab + axitinib was added (CAVEATT), 34% response rate and median PFS of 8 months for combination. As in other ICI trials in thymic carcinoma, high rates of polymyositis and other immune related AE.”
Authors: Fabio Conforti, Paolo Andrea Zucali, Laura Pala, Chiara Catani, Vincenzo Bagnardi, Isabella Sala, Paolo Della Vigna, Matteo Perrino, Paola Zagami, Chiara Corti, Sara Stucchi, Massimo Barberis, Elena Guerini-Rocco, Benedetta Di Venosa, Fabio De Vincenzo, Nadia Cordua, Armando Santoro, Giuseppe Giaccone, Tommaso Martino De Pas
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023